OBJECTIVES/HYPOTHESIS: To compare the clinical and cost outcomes of transoral robotic surgery (TORS) versus open procedures following the U.S. Food and Drug Administration approval in December 2009. STUDY DESIGN: Retrospective analysis of the Nationwide Inpatient Sample from 2008 to 2011. METHODS: Elective partial pharyngectomies and partial glossectomies for neoplasm were identified by International Classification of Diseases, 9th Revision, Clinical Modification code. RESULTS: TORS represented 2.1% in 2010 and 2.2% in 2011 of all transoral ablative procedures. Patients undergoing open partial pharyngectomy for oropharyngeal neoplasms (n = 1426) had more severe illness compared to TORS (n = 641). However, after controlling for minor-to-moderate severity of illness, open partial pharyngectomy was associated with longer hospital stay (5.2 vs. 3.7 days, P < 0.001), higher charge ($98,228 vs. $67,317, P < 0.001), higher cost ($29,365 vs. $20,706, P < 0.001), higher rates of tracheostomy and gastrostomy tube placement, and more wound and bleeding complications. TORS was associated with a higher rate of dysphagia (19.5% vs. 8.0%, P < 0.001). The lower cost of TORS remained significant in the major-to-extreme severity of illness group but was associated with higher complication rates when compared to open cases of the same severity of illness. A similar analysis of TORS partial glossectomy for base of tongue tumors had similar cost and length of stay benefits, whereas TORS partial glossectomy for anterior tongue tumors revealed longer hospital stays and no benefit in charge or cost compared to open. CONCLUSIONS: Early data demonstrate a clinical and cost benefit in TORS partial pharyngectomy and partial glossectomy for the base of tongue but no benefit in partial glossectomy of the anterior tongue. It is likely that anatomic accessibility and extent of surgery factor into the effectiveness of TORS.
OBJECTIVES/HYPOTHESIS: To compare the clinical and cost outcomes of transoral robotic surgery (TORS) versus open procedures following the U.S. Food and Drug Administration approval in December 2009. STUDY DESIGN: Retrospective analysis of the Nationwide Inpatient Sample from 2008 to 2011. METHODS: Elective partial pharyngectomies and partial glossectomies for neoplasm were identified by International Classification of Diseases, 9th Revision, Clinical Modification code. RESULTS:TORS represented 2.1% in 2010 and 2.2% in 2011 of all transoral ablative procedures. Patients undergoing open partial pharyngectomy for oropharyngeal neoplasms (n = 1426) had more severe illness compared to TORS (n = 641). However, after controlling for minor-to-moderate severity of illness, open partial pharyngectomy was associated with longer hospital stay (5.2 vs. 3.7 days, P < 0.001), higher charge ($98,228 vs. $67,317, P < 0.001), higher cost ($29,365 vs. $20,706, P < 0.001), higher rates of tracheostomy and gastrostomy tube placement, and more wound and bleeding complications. TORS was associated with a higher rate of dysphagia (19.5% vs. 8.0%, P < 0.001). The lower cost of TORS remained significant in the major-to-extreme severity of illness group but was associated with higher complication rates when compared to open cases of the same severity of illness. A similar analysis of TORS partial glossectomy for base of tongue tumors had similar cost and length of stay benefits, whereas TORS partial glossectomy for anterior tongue tumors revealed longer hospital stays and no benefit in charge or cost compared to open. CONCLUSIONS: Early data demonstrate a clinical and cost benefit in TORS partial pharyngectomy and partial glossectomy for the base of tongue but no benefit in partial glossectomy of the anterior tongue. It is likely that anatomic accessibility and extent of surgery factor into the effectiveness of TORS.
Authors: Brett G M Hughes; Vikram K Jain; Teresa Brown; Ann-Louise Spurgin; Gemma Hartnett; Jacqui Keller; Lee Tripcony; Mark Appleyard; Robert Hodge Journal: Head Neck Date: 2012-05-18 Impact factor: 3.147
Authors: Richard Lee; Casey K Ng; Shahrokh F Shariat; Anna Borkina; Robert Guimento; Kevin F Brumit; Douglas S Scherr Journal: BJU Int Date: 2011-04-18 Impact factor: 5.588
Authors: David M Cognetti; Adam J Luginbuhl; Anthony L Nguyen; Joseph M Curry Journal: Otolaryngol Head Neck Surg Date: 2012-04-10 Impact factor: 3.497
Authors: Gregory S Weinstein; Bert W O'Malley; J Scott Magnuson; William R Carroll; Kerry D Olsen; Lixia Daio; Eric J Moore; F Christopher Holsinger Journal: Laryngoscope Date: 2012-07-02 Impact factor: 3.325
Authors: Justin B Dimick; Steven L Chen; Paul A Taheri; William G Henderson; Shukri F Khuri; Darrell A Campbell Journal: J Am Coll Surg Date: 2004-10 Impact factor: 6.113
Authors: Joseph Zenga; Jasmina Suko; Dorina Kallogjeri; Patrik Pipkorn; Brian Nussenbaum; Ryan S Jackson Journal: Laryngoscope Date: 2017-04-20 Impact factor: 3.325
Authors: Jiawei Yuan; Bradley Malin; François Modave; Yi Guo; William R Hogan; Elizabeth Shenkman; Jiang Bian Journal: J Biomed Inform Date: 2016-12-19 Impact factor: 6.317
Authors: Kevin Motz; Hsien-Yen Chang; Harry Quon; Jeremy Richmon; David W Eisele; Christine G Gourin Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-06-01 Impact factor: 6.223
Authors: Anurag K Singh; Christina Mimikos; Adrienne Groman; Shiva Dibaj; Alexis J Platek; David M Cohan; Wesley L Hicks; Vishal Gupta; Hassan Arshad; Moni A Kuriakose; Graham W Warren; Mary E Platek Journal: Oncotarget Date: 2017-08-10